EDG receptor signaling in hepatic stem cell activation

肝干细胞激活中的 EDG 受体信号传导

基本信息

  • 批准号:
    6572518
  • 负责人:
  • 金额:
    $ 14.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-03-15 至 2005-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Proliferation and differentiation of hepatic oval (stem) cells are regulated by a variety of factors, yet not completely understood. Lysophosphatidic acid (LPA) and sphingosine-l-phosphate (S1P) are {phospholipid growth factors}, which regulate cell proliferation and differentiation, increase motility, and even enhance survival in several cell types. Cellular effects of LPA and S1P are mediated mainly via G-protein coupled receptors encoded by Endothelial Differentiation Genes (EDG). We have found that induction of oval cell proliferation during liver damage was associated with the expression of several types of EDG receptors, predominantly in small oval cells. We, therefore, hypothesize that the EDG expression profiles and the corresponding cellular responses to EDG receptor ligands LPA and S1P are specific for hepatic stem cells at various stages of differentiation {to mature hepatocytes/cholangiocytes}. Moreover, we propose that differential expression of EDG receptors may be a necessary part of the mechanism responsible for the activation of hepatic stem cells. The goals of this project are to explore hepatic EDG receptor profiles {during liver injury in vivo}, and {determine oval cell responses and EDG-mediated signaling by LPA/S1P in vitro}. These goals will be achieved by pursuing two Specific Aims: (1) to characterize the pattern of hepatic EDG receptors at different stages of mouse chronic liver injury accompanied by proliferation of hepatic oval cells; and (2) To identify how EDG-mediated cell signaling by LPA/S1P will regulate hepatic oval cell activation, proliferation and differentiation in culture. The results will establish the expression profiles and localization of EDG receptors during hepatic oval cell proliferation and differentiation, and will determine intracellular signaling pathways of oval cell activation by LPA/S1P. Successful accomplishment of the project will provide novel information exploring lipid mediator signaling in stem cells, which will have a great value to develop new insights in stem cell biology. Finally, we believe that the data produced in the field of lipid signaling mechanisms during proliferation and differentiation of stem cells can be used to generate an R01, which will further expand our understanding of stem cell biology.
描述(由申请人提供):肝卵圆(干)细胞的增殖和分化受多种因素调节,但尚未完全了解。溶血磷脂酸(LPA)和鞘氨醇-1-磷酸(S1 P)是{磷脂生长因子},其调节细胞增殖和分化,增加运动性,甚至增强几种细胞类型的存活。LPA和S1 P的细胞效应主要通过内皮分化基因(EDG)编码的G蛋白偶联受体介导。我们已经发现,肝损伤期间卵圆细胞增殖的诱导与几种类型的EDG受体的表达有关,主要是在小卵圆细胞中。因此,我们假设EDG表达谱和对EDG受体配体LPA和S1 P的相应细胞应答对于处于分化{至成熟肝细胞/胆管细胞}的各个阶段的肝干细胞是特异性的。此外,我们认为EDG受体的差异表达可能是肝干细胞活化机制的必要组成部分。本项目的目的是探索肝脏EDG受体谱{在体内肝损伤期间},并{确定卵圆细胞反应和EDG介导的信号传导通过LPA/S1 P在体外}。这些目标将通过追求两个特定目标来实现:(1)表征伴随肝卵圆细胞增殖的小鼠慢性肝损伤不同阶段的肝EDG受体模式;和(2)鉴定LPA/S1 P介导的EDG细胞信号传导如何调节培养物中肝卵圆细胞的活化、增殖和分化。本研究结果将建立肝卵圆细胞增殖分化过程中EDG受体的表达谱和定位,并将确定LPA/S1 P激活卵圆细胞的细胞内信号通路。该项目的成功完成将为探索干细胞中脂质介导的信号转导提供新的信息,对开发干细胞生物学的新见解具有重要价值。最后,我们相信干细胞增殖和分化过程中脂质信号机制领域产生的数据可用于生成R 01,这将进一步扩展我们对干细胞生物学的理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(4)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STANISLAV I SVETLOV其他文献

STANISLAV I SVETLOV的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STANISLAV I SVETLOV', 18)}}的其他基金

Recombinant hepatic argininosuccinate synthase (rASS) for treatment of sepsis/end
重组肝精氨酸琥珀酸合酶(rASS)用于治疗脓毒症/终点
  • 批准号:
    8249357
  • 财政年份:
    2011
  • 资助金额:
    $ 14.5万
  • 项目类别:
Recombinant hepatic argininosuccinate synthase (rASS) for treatment of sepsis/end
重组肝精氨酸琥珀酸合酶(rASS)用于治疗脓毒症/终点
  • 批准号:
    8121317
  • 财政年份:
    2011
  • 资助金额:
    $ 14.5万
  • 项目类别:
Novel diagnostic and safety biomarkers of liver injury and hepatotoxicity
肝损伤和肝毒性的新型诊断和安全生物标志物
  • 批准号:
    8012889
  • 财政年份:
    2010
  • 资助金额:
    $ 14.5万
  • 项目类别:
Novel diagnostic and safety biomarkers of liver injury and hepatotoxicity
肝损伤和肝毒性的新型诊断和安全生物标志物
  • 批准号:
    7404944
  • 财政年份:
    2006
  • 资助金额:
    $ 14.5万
  • 项目类别:
Novel diagnostic and safety biomarkers of liver injury and hepatotoxicity
肝损伤和肝毒性的新型诊断和安全生物标志物
  • 批准号:
    7868731
  • 财政年份:
    2006
  • 资助金额:
    $ 14.5万
  • 项目类别:
Novel diagnostic and safety biomarkers of liver injury and hepatotoxicity
肝损伤和肝毒性的新型诊断和安全生物标志物
  • 批准号:
    7578886
  • 财政年份:
    2006
  • 资助金额:
    $ 14.5万
  • 项目类别:
EDG receptor signaling in hepatic stem cell activation
肝干细胞激活中的 EDG 受体信号传导
  • 批准号:
    6718949
  • 财政年份:
    2003
  • 资助金额:
    $ 14.5万
  • 项目类别:

相似海外基金

Prevention of age-related hearing loss using bone marrow transplantation
利用骨髓移植预防与年龄相关的听力损失
  • 批准号:
    23K08999
  • 财政年份:
    2023
  • 资助金额:
    $ 14.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Tuning tyrosine kinase signalling to improve haematopoietic stem cell expansion and bone marrow transplantation
调节酪氨酸激酶信号传导以改善造血干细胞扩增和骨髓移植
  • 批准号:
    2889841
  • 财政年份:
    2023
  • 资助金额:
    $ 14.5万
  • 项目类别:
    Studentship
A Novel Bone Marrow Transplantation Approach for Sickle Cell Disease Using Targeted Marrow Irradiation
使用靶向骨髓照射治疗镰状细胞病的新型骨髓移植方法
  • 批准号:
    10737358
  • 财政年份:
    2023
  • 资助金额:
    $ 14.5万
  • 项目类别:
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
  • 批准号:
    10722602
  • 财政年份:
    2022
  • 资助金额:
    $ 14.5万
  • 项目类别:
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
  • 批准号:
    10368246
  • 财政年份:
    2022
  • 资助金额:
    $ 14.5万
  • 项目类别:
1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
1/2A III 期随机试验,比较无关供体骨髓移植与免疫抑制治疗对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者的影响
  • 批准号:
    10600143
  • 财政年份:
    2022
  • 资助金额:
    $ 14.5万
  • 项目类别:
1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
1/2A III 期随机试验,比较无关供体骨髓移植与免疫抑制治疗对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者的影响
  • 批准号:
    10370775
  • 财政年份:
    2022
  • 资助金额:
    $ 14.5万
  • 项目类别:
The mycobiota, bone marrow transplantation, and clinical outcomes
真菌群、骨髓移植和临床结果
  • 批准号:
    10415200
  • 财政年份:
    2021
  • 资助金额:
    $ 14.5万
  • 项目类别:
The mycobiota, bone marrow transplantation, and clinical outcomes
真菌群、骨髓移植和临床结果
  • 批准号:
    10303678
  • 财政年份:
    2021
  • 资助金额:
    $ 14.5万
  • 项目类别:
Bone Marrow Transplantation in Human Disease
骨髓移植治疗人类疾病
  • 批准号:
    10196999
  • 财政年份:
    2019
  • 资助金额:
    $ 14.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了